INTRODUCTION
Biochemical and pharmacological properties of schiff bases have been extensively investigated owing to their potential applications such as antibacterial (1- 2), antiviral (3) (4) , anti-inflammatory (5-6), anti-tubercular (7) (8) , antileprosy (9) , antileukemia (10) activities.
Because these bases appear to have such wide applications, many investigators are now focusing attention on the possibility of developing chemotherapeutic agents from schiff bases (11) (12) (13) . Schiff bases of thiosemicarbazone and their derivatives also possess potential anticancer activities. 1, 2-naphthaquinone-2-thiosemicarbazone and its metal complexes have pronounced anticancer activities against MCF 7 human breast cancer cells (14) . Copper (II) complex of thiosemicarbazone derivatives showed potent anticancer activities against human leukemia cell lines K562 and U937 (15 (16) . The anticancer activities of pyridine-2-carboxaldehyde thiosemicarbazones and a series of di-2-pyridyl ketone thiosemicarbazone ligands have also been reported in literature (17) . In the present paper we have studied the anticancer activities of acetone thiosemicarbazone (ATSC) against Ehrlich Ascites Carcinoma (EAC) cells in swiss albino mice.
MATERIALS AND METHODS

Synthesis of ATSC
The procedure for the synthesis of ATSC was similar to that described in the literature (18) . Acetone and thiosemicarbazide were mixed together in 1:1 molar ratio and refluxed for a period of 3-4 hours and then distilled to half of the total volume. The solution was then allowed to stand overnight till a white crystalline product was obtained. The crystals were recrystallized, filtered, washed several times with ethanol and dried at 60°C in an oven. It was then cooled to room temperature and stored in a desiccator.
Characterization of the compound (ATSC)
The formation and purity of the compound was confirmed by taking melting points and infrared spectrum. The LD 50 value was determined following conventional methods (19) . The test compound was dissolved in 3% DMSO and was injected intraperitoneally to six groups of mice (each group containing six animals) with different doses of [10, 20, 
Cell growth inhibition
In vivo tumour cell growth inhibition was carried out by the method as described in the literature (20) . For this study five groups of mice (6 in each group) were used. For therapeutic evaluation 13.6x10 5 The number of EAC cell 136 x 10 4 per ml was inoculated into five groups of mice (six in each group) on day 0. Three groups were treated with ATSC at the doses of 1.0 mg/kg (i.p.), 1.5 mg/kg (i.p.) and 2.0 mg/kg (i.p.) respectively after 24 hours of EAC cell inoculation in mice and continued for 5 days.
Group four was treated bleomycin at the doses of 0.3 mg/kg (i.p.). Fifth group was considered as untreated control. Cell growth inhibition was determined on day 6 by counting EAC cells/ml. Results were shown in mean ± SEM and compared with normal mice. * P < 0.05 between control and treated group.
Haematological parameters were found to be altered from normal values along with the growth of tumour. Haemoglobin content and RBC counts were found to be decreased but WBC counts were found to be increased after inoculation of EAC cells in swiss albino mice. After treatment with the test compound at doses 1.0 1.5 and 2.0mg/kg (i.p), it was observed that the parameters restored more or less towards normal.
During treatment of normal mice with ATSC, haemoglobin content and RBC counts were found to be decreased but WBC counts were found to be increased as shown here ( Figures 5-7 ) for the first 10 days. After treatment period, it was observed that the parameters restored almost towards normal (Figures 5-7) .
Effects of the test compounds on enhancement of total peritoneal cells in normal mice and mice treated with the test compounds at different doses were shown in Table 3 . Treatment with the test compound at increasing doses resulted in increase of normal peritoneal cells as well as macrophages. The number of EAC cell 136 ± 10 4 per ml was inoculated into five groups of mice (six in each group) on day 0. Three groups were treated with ATSC at the doses of 1.0 mg/kg (i.p.), 1.5 mg/kg (i.p.) and 2.0 mg/kg (i.p.) respectively after 24 hours of EAC cell inoculation in mice and continued for 10 days.
Group four was treated bleomycin at the doses of 0. 
